ASH 2022 | Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the design and rationale of the Mylox-1 trial (NCT04679870), which is assessing the use of the oral LOXL-2 inhibitor GB2064 in myelofibrosis (MF). Prof. Verstovsek explains that novel agents such as GB2064 that can counteract the fibrosis in the bone marrow may improve bone marrow function, particularly if combined with JAK inhibitors, but highlights that this has yet to be confirmed. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; AstraZeneca: Research Funding; ItalPharma: Research Funding; Novartis: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; Promedior: Research Funding; CTI BioPharma Corp.: Research Funding; Gilead: Research Funding; Sierra Oncology: Consultancy, Research Funding; Roche: Research Funding; Protagonist Therapeutics: Research Funding; PharmaEssentia: Research Funding; Blueprints Medicines Corp.: Research Funding; Celgene: Consultancy, Research Funding; Genentech: Research Funding; Pragmatist: Consultancy; Constellation Pharmaceuticals: Consultancy.
